The product label - How pharmacokinetics and pharmacodynamics reach the prescriber

被引:17
作者
Marroum, PJ [1 ]
Gobburu, J [1 ]
机构
[1] US FDA, Ctr Drug Evaluat & Res, OPS, OCPB,DPE1, Rockville, MD 20857 USA
关键词
D O I
10.2165/00003088-200241030-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The product label, or package insert, is the 'manual' for the safe and effective use of a drug. Important pharmacokinetic and pharmacodynamic properties of a drug product should appear in the label under specific sections, as required in the Code of Federal Regulations (CFR), using a format and language recommended by the Food and Drug Administration (FDA) in various guidances to the industry. The relevant regulations and guidance documents impacting on how this information is conveyed to the healthcare professional are discussed, with special emphasis on how the new proposed rule will impact upon how information is to be conveyed. With the availability of new clinical pharmacology information not available at the time of approval, package inserts for older drugs should be updated to reflect the new data and recommend the proper dosage regimen, enabling prescribers to optimise drug therapy and minimise possible adverse events.
引用
收藏
页码:161 / 169
页数:9
相关论文
共 16 条
[1]  
*ASTR, 2001, TOPR XL MET SUCC EXT
[2]  
*BRIST MYERS SQUIB, 2001, AV IRB PACK INS
[3]  
*NAT BIOS INC, 1992, FOC GROUP REP PHYS P
[4]   OPPORTUNITIES FOR INTEGRATION OF PHARMACOKINETICS, PHARMACODYNAMICS, AND TOXICOKINETICS IN RATIONAL DRUG DEVELOPMENT [J].
PECK, CC ;
BARR, WH ;
BENET, LZ ;
COLLINS, J ;
DESJARDINS, RE ;
FURST, DE ;
HARTER, JG ;
LEVY, G ;
LUDDEN, T ;
RODMAN, JH ;
SANATHANAN, L ;
SCHENTAG, JJ ;
SHAH, VP ;
SHEINER, LB ;
SKELLY, JP ;
STANSKI, DR ;
TEMPLE, RJ ;
VISWANATHAN, CT ;
WEISSINGER, J ;
YACOBI, A .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) :465-473
[5]  
*PFIZ, 2001, VIAGR SILD CITR PACK
[6]   Assessment and reporting of clinical pharmacology information in drug labeling - Commentary [J].
Spyker, DA ;
Harvey, ED ;
Harvey, BE ;
Harvey, AM ;
Rumack, BH ;
Peck, CC ;
Atkinson, AJ ;
Woosley, RL ;
Abernethy, DR ;
Cantilena, LR .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (03) :196-200
[7]  
*US DEP HHS PUBL H, 1999, FDA GUID IND POP PHA
[8]  
*US DEP HHS PUBL H, 1997, FDA GUID IND DRUG ME
[9]  
*US DEP HHS PUBL H, 1997, DRAFT FDA GUID IND F
[10]  
*US DEP HHS PUBL H, 1998, FDA DRAFT GUID IND G